Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Abeona Therapeutics

CRISPR Therapeutics

Investing in biotech stock can provide investors with immense rewards but also substantial risks. The key is finding the right balance.

3 Biotech Blockbusters to Turn $5,000 Into $50,000

After losing some value lately, a hammer chart pattern has been formed for VAXART, INC. (VXRT), indicating that the stock has found support.

Bears are Losing Control Over VAXART, INC. (VXRT), Here's Why It's a 'Buy' Now

Start Time: 16:30 January 1, 0000 5:01 PM ET Vaxart, Inc. (NASDAQ:VXRT ) Q2 2023 Earnings Conference Call August 03, 2023, 16:30 PM ET Company Participants Andrei Floroiu - President and CEO James Cummings - Chief Medical Officer Sean Tucker - SVP and Chief Scientific Officer Phil Lee - CFO Brant Biehn - SVP and Business Operations Conference Call Participants Charles Duncan - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Operator Greetings, and welcome to the Vaxart Business Update and Second Quarter 2023 Financial Results Conference Call.

Vaxart, Inc. (VXRT) Q2 2023 Earnings Call Transcript

VAXART, INC. (VXRT) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19.

VAXART, INC. (VXRT) Reports Q2 Loss, Tops Revenue Estimates

On track to report topline data from Phase 2 GI.1 norovirus vaccine challenge study in Q3 2023 Cash runway extended into Q3 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.

Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results

SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today held its Annual Meeting of Shareholders in a virtual-only format. Preliminary results from the Annual Meeting indicate that all four proposals were approved by Vaxart shareholders.

Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement

SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today encourages its stockholders of record on April 28, 2023, to vote on its proxy if they have not yet done so. The Company urges a yes vote on all Proxy proposals. Leading proxy advisors ISS and Glass Lewis are both advising shareholders to vote in favor of all proposals.

Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET

Vaxart (NASDAQ: VXRT ) stock is taking a beating on Wednesday as investors react to the company announcing a proposed public share offering. According to a press release from Vaxart, the company is holding that public offering today.

Why Is Vaxart (VXRT) Stock Down 25% Today?

SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the pricing of its underwritten public offering of 16,000,000 shares of its common stock, for gross proceeds of approximately $15,000,000, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Vaxart. The offering is expected to close on or about June 9, 2023, subject to customary closing conditions. In addition, Vaxart has granted to the underwriter a 30-day option to purchase up to 2.4 million additional shares of its common stock.

Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has commenced an underwritten public offering of its common stock. In addition, Vaxart expects to grant to the underwriter a 30-day option to purchase up to an additional 15% of shares of the common stock sold in the public offering. All of the securities in the offering are to be sold by Vaxart. The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Vaxart, Inc. Announces Proposed Public Offering of Common Stock

Vaxart, Inc. (NASDAQ:VXRT ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Edward Berg - Senior Vice President and General Counsel Andrei Floroiu - Chief Executive Officer James Cummings - Chief Medical Officer Sean Tucker - Founder & Chief Scientific Officer Phil Lee - Chief Financial Officer Conference Call Participants Mayank Mamtani - B. Riley Securities Roger Song - Jefferies Operator Greetings and welcome to Vaxart Business Update and First Quarter 2023 Financial Results Conference Call.

Vaxart, Inc. (VXRT) Q1 2023 Earnings Call Transcript

On track to report key top line data from two Phase 2 norovirus vaccine studies mid-year and in Q3 2023 Continue to anticipate cash runway into Q2 2024 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.

Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results

Company to provide a detailed overview of its norovirus clinical program

Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus

Vaxart, Inc. (NASDAQ:VXRT ) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants Brant Biehn - Senior Vice President, Business Operations Andrei Floroiu - Chief Executive Officer James Cummings - Chief Medical Officer Sean Tucker - Founder & Chief Scientific Officer Phil Lee - Chief Financial Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Operator Greetings.

Vaxart, Inc. (VXRT) Q4 2022 Earnings Call Transcript

Prioritizing oral bivalent norovirus candidate, one of the most advanced norovirus vaccines in development

Vaxart Provides Business Update and Full Year 2022 Financial Results

Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15

Akebia Therapeutics

Eiger BioPharmaceuticals

Protalix Biotherapeutics

Penny stocks to watch before next year. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 4 To Watch Before 2023

Mr. Lee brings almost 15 years of experience in strategy, M&A and partnering on more than $20 billion in transactions

Vaxart Names Phillip Lee as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego on Tuesday, November 29, 2022 at 1:50 p.m. PT / 4:50 p.m. ET.

Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29

Vaxart, Inc. (NASDAQ:VXRT ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Brant Biehn - SVP, Business Operations Cezar Floroiu - CEO, President & Director Sean Tucker - SVP & Chief Scientific Officer James Cummings - Chief Medical Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Sahil Kazmi - B. Riley Securities FBR Operator Greetings, and welcome to the Vaxart's Third Quarter 2022 Business Update and Financial Results Conference Call.

Vaxart, Inc. (VXRT) Q3 2022 Earnings Call Transcript

VAXART, INC. (VXRT) delivered earnings and revenue surprises of 4.17% and 100%, respectively, for the quarter ended September 2022.

VAXART, INC. (VXRT) Reports Q3 Loss, Misses Revenue Estimates

Growing body of clinical evidence supports transformational potential of Vaxart's oral vaccine platform

Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results

VAXART, INC. (VXRT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

VAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Plug Power

Select analysts believe these industry game changers can skyrocket over the next year.

News for Vaxart Stock (VXRT)